Patients whose Alzheimer's symptoms start before age 65 have more extensive deposits of tau, the protein considered a hallmark of the disease, than patients whose symptoms begin at 65 or older. A new study found that tau accumulates at more than twice the rate in the younger patients and spreads widely through the brain. The work was published in Science Translational Medicine on Nov. 4 and was supported by funding from the National Institute on Aging.
The researchers say the pattern may help explain why early-onset Alzheimer's typically progresses faster and is more likely to produce unusual syndromes affecting language, visual and spatial abilities, and executive functioning. Early-onset patients make up about 5% of Alzheimer's cases. In this group, roughly 1 in 5 presented with a non-memory-dominant form of the disease, while more than 99% of the late-onset patients whose presentations were documented had a memory-dominant form.
The analysis drew on 390 patients from the Longitudinal Early-Onset Alzheimer's Disease Study, with an average age of 59, and 211 late-onset patients from the Alzheimer's Disease Neuroimaging Initiative, with an average age of 78. All had mild cognitive impairment or mild dementia due to Alzheimer's, and all had PET scans showing amyloid, an early biomarker of the disease. A subset had repeat tau PET scans over an average follow-up of two to three years, which let the team track how tau changed over time.
Konstantinos Chiotis, the first author, said the team does not yet know why Alzheimer's develops so early in some people. Patients with a known disease-causing mutation were excluded, and Chiotis said a key open question is whether other genetic factors explain the more aggressive tau pathology seen in younger patients.
The two drugs approved to slow Alzheimer's progression target amyloid, yet in this study the differences between early- and late-onset disease were much greater for tau than for amyloid. The study did not test treatments. Senior author Gil Rabinovici said tau accumulation was particularly aggressive in early-onset patients and was more strongly related to progression of memory loss, and he suggested that younger patients may be good candidates for clinical trials combining treatments that target amyloid and tau.